Rhythm Pharmaceuticals, Inc. (RYTM)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Rhythm Pharmaceuticals, Inc. (RYTM)
Go deeper and ask any question about RYTM
Company Performance
Current Price
as of Oct 03, 2024$48.58
P/E Ratio
N/A
Market Cap
$2.97B
Description
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryBiotechnology
- TickerRYTM
- Price$48.58-4.76%
Trading Information
- Market Cap$2.97B
- Float89.24%
- Average Daily Volume (1m)489,174
- Average Daily Volume (3m)433,405
- EPS-$4.37
Company
- Revenue$101.78M
- Rev Growth (1yr)51.28%
- Net Income-$32.26M
- Gross Margin89.26%
- EBITDA Margin-137.86%
- EBITDA-$40.09M
- EV$2.44B
- EV/Revenue23.96
- P/EN/A
- P/S29.12